cerevel.com - CERE Business Value to Revenue

Public company logo of Cerevel Therapeutics, Inc. (CERE)

Cerevel Therapeutics (CERE) focuses on developing cutting-edge medications to combat Alzheimer's disease and schizophrenia. The enterprise value-to-revenue multiple confirms market interest in these developments, with representing the latest level. Optimism is bolstered by long-term patent protection for target drugs and a successful merger with a pharmaceutical behemoth while maintaining scientific continuity.

Cerevel Corp (CERE): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

CERE (Cerevel Therapeutics, Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
- issuer market value details:
- money and cash flow information:
Fundamental company valuation:CERE, Cerevel Therapeutics, Inc.
Mass-produced product of cerevel.com

When selecting equity assets, reliability is assessed by comparing market capitalization adjusted for net debt to sales volume. This calculation determines the premium for future growth; however, for Cerevel Therapeutics (CERE), the risk of overvaluation is amplified by geopolitical barriers in component logistics and patent disputes, making a sharp change in the EV/Sales ratio a signal of a disconnect between quotes and actual revenue.

Direct competitors

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|KTTA: Company Value to Revenue|Business Value to Revenue CRGT (cortigent.com)|ATXI: EV/Sales Multiple|BCLI (BrainStorm Cell Therapeutics) - Enterprise Value-to-Revenue Ratio|CARA (Cara Therapeutics Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio CHRO|Company Value to Revenue ELYM (Eliem Therapeutics)|Enterprise Value-to-Revenue Ratio ITCI (Intra-Cellular Therapies Inc.)|EV/Sales Multiple LBPH (Longboard Pharma)|EV/Sales Multiple Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - EV/Sales Multiple|Business Value to Revenue NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Company Value to Revenue|Company Value to Revenue Ratio SNPX|Company Value to Revenue TRVN|Enterprise Value-to-Revenue Ratio VIGL|EV/Sales Multiple WENA